-
1.
公开(公告)号:US20070265315A1
公开(公告)日:2007-11-15
申请号:US11775457
申请日:2007-07-10
申请人: Jacques Dumas , William Scott , Bernd Riedl
发明人: Jacques Dumas , William Scott , Bernd Riedl
IPC分类号: A61K31/44 , A61P35/00 , C07D211/72
CPC分类号: C07D213/89 , C07D215/60 , C07D217/08
摘要: This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angogenesis disorders.
摘要翻译: 本发明涉及含有吡啶,喹啉或异喹啉官能团的脲化合物,其在氮杂原子处被氧化并且可用于治疗(i)raf介导的疾病,例如癌症,(ii)p38介导的疾病,例如 炎症和骨质疏松症,和(iii)VEGF介导的疾病,如血管发生障碍。
-
2.Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas 失效
标题翻译: 使用喹啉基,异喹啉基或吡啶基脲来抑制RAF激酶公开(公告)号:US20060019990A1
公开(公告)日:2006-01-26
申请号:US11158048
申请日:2005-06-22
申请人: Jacques Dumas , Bernd Riedl , Uday Khire , Robert Sibley , Holia Hatoum-Mokdad , Mary-Katherine Monahan , David Gunn , Timotthy Lowinger , William Scott , Roger Smith , Jill Wood
发明人: Jacques Dumas , Bernd Riedl , Uday Khire , Robert Sibley , Holia Hatoum-Mokdad , Mary-Katherine Monahan , David Gunn , Timotthy Lowinger , William Scott , Roger Smith , Jill Wood
IPC分类号: A61K31/4709 , A61K31/444 , C07D401/02
CPC分类号: C07D213/40
摘要: The invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
摘要翻译: 本发明涉及一组喹啉基,异喹啉基和吡啶基脲,它们在治疗raf介导的疾病中的用途,以及含有用于这种治疗的这些尿素的药物组合物。
-
3.Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors 有权
标题翻译: 羟基,ω-羧基芳基取代的二苯基脲和其衍生物作为raf激酶抑制剂公开(公告)号:US07528255B2
公开(公告)日:2009-05-05
申请号:US10071248
申请日:2002-02-11
申请人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , William Scott , Roger Smith , Jill Wood
发明人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , William Scott , Roger Smith , Jill Wood
IPC分类号: C07D211/72 , C07D213/62 , C07D213/78
CPC分类号: C07D295/192 , A61K31/17 , A61K31/18 , A61K31/24 , A61K31/341 , A61K31/40 , A61K31/4035 , A61K31/44 , A61K31/4439 , A61K31/4453 , A61K31/495 , A61K31/496 , A61K31/5375 , A61K31/5377 , C07C275/28 , C07C275/30 , C07C275/32 , C07C275/36 , C07C275/40 , C07C311/29 , C07C317/22 , C07D209/46 , C07D209/48 , C07D209/50 , C07D213/75 , C07D213/80 , C07D213/81 , C07D295/073 , C07D295/12 , C07D295/13 , C07D295/135 , C07D295/18 , C07D401/12 , C07F7/1804
摘要: The invention relates to the use of a group of aryl ureas in treating raf mediated diseases and pharmaceutical compositions for use in such therapy of the formula wherein, Y is NHR Hal is chlorine or bromine, R is H, CH3 or CH2OH, and X1 to X7 are each, independently, H, OH or —OC(O)C1-C4 alkyl, or a salt purified stereoisomer thereof, wherein at least one of X1 to X7 is OH or —OC(O)C1-C4 alkyl.
摘要翻译: 本发明涉及一组芳基脲在治疗raf介导的疾病中的用途以及用于下列治疗的药物组合物:其中Y是NHR Hal是氯或溴,R是H,CH3或CH2OH,X1至 X 7各自独立地为H,OH或-OC(O)C 1 -C 4烷基或其盐纯化的立体异构体,其中X 1至X 7中的至少一个为OH或-OC(O)C 1 -C 4烷基。
-
4.
公开(公告)号:US07351834B1
公开(公告)日:2008-04-01
申请号:US09889227
申请日:2000-01-12
申请人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , William Scott , Roger A. Smith , Jill E. Wood , Mary-Katherine Monahan , Reina Natero , Joel Renick , Robert Sibley
发明人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , William Scott , Roger A. Smith , Jill E. Wood , Mary-Katherine Monahan , Reina Natero , Joel Renick , Robert Sibley
IPC分类号: C07D213/30 , A61K31/44
CPC分类号: C07D209/48 , C07C251/48 , C07C275/28 , C07C275/30 , C07C275/32 , C07C275/36 , C07C275/40 , C07C311/29 , C07C317/22 , C07D207/09 , C07D209/46 , C07D213/74 , C07D213/75 , C07D213/79 , C07D213/81 , C07D213/82 , C07D295/12 , C07D295/13 , C07D295/135 , C07D295/18 , C07D295/192 , C07D307/14 , C07D401/12
摘要: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
摘要翻译: 本发明涉及一组芳基脲在治疗raf介导的疾病中的用途,以及用于此类治疗的药物组合物。
-
5.omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors 有权
标题翻译: ω-羧基芳基取代的二苯脲作为p38激酶抑制剂公开(公告)号:US20080027061A1
公开(公告)日:2008-01-31
申请号:US11845597
申请日:2007-08-27
申请人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , William Scott , Roger Smith , Jill Wood , Mary-Katherine Monahan , Reina Natero , Joel Renick , Robert Sibley
发明人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , William Scott , Roger Smith , Jill Wood , Mary-Katherine Monahan , Reina Natero , Joel Renick , Robert Sibley
IPC分类号: A61K31/535 , A61K31/17 , A61P19/02 , A61K31/495
CPC分类号: A61K31/5377 , A61K31/17 , A61K31/18 , A61K31/24 , A61K31/341 , A61K31/40 , A61K31/4035 , A61K31/44 , A61K31/4439 , A61K31/4453 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5375 , Y02A50/401 , Y02A50/411 , Y02A50/414 , Y02A50/473
摘要: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
摘要翻译: 本发明涉及一组芳基脲在治疗p38介导的疾病中的用途,以及用于此类治疗的药物组合物。
-
6.
公开(公告)号:US20070244120A1
公开(公告)日:2007-10-18
申请号:US11768112
申请日:2007-06-25
申请人: Jacques Dumas , Uday Khire , Timothy Lowinger , Holger Paulsen , Bernd Riedl , William Scott , Roger Smith , Jill Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Wendy Lee , Aniko Redman , Robert Sibley , Joel Renick
发明人: Jacques Dumas , Uday Khire , Timothy Lowinger , Holger Paulsen , Bernd Riedl , William Scott , Roger Smith , Jill Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Wendy Lee , Aniko Redman , Robert Sibley , Joel Renick
IPC分类号: A61K31/5377 , A61K31/09 , A61K31/136 , A61K31/381 , A61K31/4164 , A61K31/4196 , A61K31/42 , A61K31/426 , C07D401/12 , C07D231/10 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/4709 , A61K31/496 , A61K31/497
CPC分类号: C07D231/40 , C07D207/34 , C07D259/00 , C07D261/14 , C07D271/113 , C07D285/135 , C07D333/36 , C07D401/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
摘要翻译: 治疗由raf激酶介导的肿瘤与取代的脲化合物及其化合物本身的方法。
-
7.OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS 有权
标题翻译: 作为RAF激酶抑制剂的OMEGA-CARBOXYARYL替代二苯醚公开(公告)号:US20120142742A1
公开(公告)日:2012-06-07
申请号:US13368812
申请日:2012-02-08
申请人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy B. Lowinger , William J. Scott , Roger A. Smith , Jill E. Wood
发明人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy B. Lowinger , William J. Scott , Roger A. Smith , Jill E. Wood
CPC分类号: C07C275/36 , C07C275/28 , C07C275/30 , C07C275/32 , C07C275/40 , C07C311/29 , C07C317/22 , C07D209/46 , C07D209/48 , C07D213/75 , C07D213/81 , C07D213/82 , C07D295/13 , C07D295/135 , C07D295/192 , C07D413/12
摘要: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
摘要翻译: 本发明涉及一组芳基脲在治疗raf介导的疾病中的用途,以及用于此类治疗的药物组合物。
-
8.
公开(公告)号:US20100152251A1
公开(公告)日:2010-06-17
申请号:US12692845
申请日:2010-01-25
申请人: Jacques DUMAS , William J. Scott , Bernd Riedl
发明人: Jacques DUMAS , William J. Scott , Bernd Riedl
CPC分类号: C07D213/89 , C07D215/60 , C07D217/08
摘要: This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
摘要翻译: 本发明涉及含有吡啶,喹啉或异喹啉官能团的脲化合物,其在氮杂原子处被氧化并且可用于治疗(i)raf介导的疾病,例如癌症,(ii)p38介导的疾病,例如 炎症和骨质疏松症,和(iii)VEGF介导的疾病如血管生成障碍。
-
9.
公开(公告)号:US07678811B2
公开(公告)日:2010-03-16
申请号:US11775457
申请日:2007-07-10
申请人: Jacques Dumas , William J. Scott , Bernd Riedl
发明人: Jacques Dumas , William J. Scott , Bernd Riedl
IPC分类号: C07D401/02 , A61K31/44 , A61K31/47
CPC分类号: C07D213/89 , C07D215/60 , C07D217/08
摘要: This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angogenesis disorders.
摘要翻译: 本发明涉及含有吡啶,喹啉或异喹啉官能团的脲化合物,其在氮杂原子处被氧化并且可用于治疗(i)raf介导的疾病,例如癌症,(ii)p38介导的疾病,例如 炎症和骨质疏松症,和(iii)VEGF介导的疾病,如血管发生障碍。
-
10.Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas 审中-公开
标题翻译: 使用芳基和杂芳基取代的杂环脲抑制p38激酶活性公开(公告)号:US20080300281A1
公开(公告)日:2008-12-04
申请号:US12181032
申请日:2008-07-28
申请人: Jacques Dumas , Uday Khire , Timothy B. Lowinger , Bernd Riedl , William J. Scott , Roger A. Smith , Jill E. Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Aniko Redman , Robert Sibley
发明人: Jacques Dumas , Uday Khire , Timothy B. Lowinger , Bernd Riedl , William J. Scott , Roger A. Smith , Jill E. Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Aniko Redman , Robert Sibley
IPC分类号: A61K31/4439 , A61K31/415 , A61K31/4427 , A61K31/381 , A61P19/02
CPC分类号: A61K31/381 , A61K31/415 , A61K31/4427 , A61K31/4439 , Y02A50/411
摘要: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.
摘要翻译: 本发明涉及一组芳基脲在治疗癌症以外的细胞因子介导的疾病和除了癌症以外的蛋白水解酶介导的疾病以及用于这种治疗的药物组合物中的用途。
-
-
-
-
-
-
-
-
-